Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 17 results for glatiramer

  1. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    27 June 2018
    View recommendations

    Sections for TA527

  2. Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

    Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    1 June 2014
    View recommendations

    Sections for TA303

  3. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    27 August 2014
    View recommendations

    Sections for TA320

  4. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

    Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    25 July 2018
    View recommendations

    Sections for TA533

  5. Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    22 August 2007
    View recommendations

    Sections for TA127

  6. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    19 February 2020
    View recommendations

    Sections for TA624

  7. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)

    Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

    Technology appraisal guidance
    Published
    9 June 2021
    View recommendations

    Sections for TA706

  9. Glatiramer acetate depot for multiple sclerosis [TS ID 10620]

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

    Technology appraisal guidance
    Published
    25 April 2012
    View recommendations

    Sections for TA254

  11. Past appeals and decisions

    sclerosis - beta interferon and glatiramer 22-23 September 2000 TA032 Multiple sclerosis - beta interferon and glatiramer...

  12. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    17 March 2020
    View recommendations

    Sections for TA312

  13. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

    Technology appraisal guidance
    Published
    19 May 2021
    View recommendations

    Sections for TA699

  14. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued [GID-TAG415]

    Technology appraisal guidance
    Discontinued

  15. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA767